by | Dec 19, 2024 | Chheda, Milan, Curiel, David, Diamond, Michael, Li, Yuping
— Published Date: 12/20/2024
Value Proposition: Treats brain tumors by combining a hematopoietic growth protein and cancer therapeutics to increase survival rates.
Technology Description
Researchers at Washington University in St. Louis have developed a new way to treat brain cancers by combining…
by | Jul 29, 2024 | Lenze, Eric, Reiersen, Angela
— Value Proposition: Novel method for treating short- and long-term symptoms of COVID-19 using a selective serotonin reuptake inhibitor (SSRI) and a sigma-1 receptor (S1R) agonist.
Technology Description
Researchers at Washington University in St. Louis have developed a novel method for treating …
by | May 1, 2024 | Adams, Lucas, Diamond, Michael, Fremont, Daved, Raju, Saravanan
— VLDLR-based Decoy Receptors to Prevent Alphavirus Infections
Technology Description
Researchers at Washington University in St. Louis have developed very low-density lipoprotein receptor (VLDLR) soluble decoy receptors with potent inhibitory activity in vitro and in vivo. Eastern equine encephali…
by | Feb 13, 2024 | Chheda, Milan, Diamond, Michael, Gorman, Matthew
— T-017429 Engineered Oncolytic Zika Virus Therapy for Glioblastoma
Technology Description
Researchers in the laboratories of Michael Diamond and Milan Chheda at Washington University have developed prospective treatments for glioblastoma (GBM) through the application of an engineered Zika virus (ZI…
by | Feb 2, 2024 | Asadi Jomnani, Farzad, Dolle, Roland "Ron", Piston, David
— T-020153 – Small Molecule Agonists of EphA Receptors to Ameliorate Diabetes
Technology Description
Blood glucose levels (left), post-treatment plasma glucagon (center) in WCDD301 treated NOD (non-obese diabetic) mice with moderate hyperglycemia. Blood glucose levels (right) in Streptozotocin-ind…